SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 20, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2nd Annual Healthcare Conference being held at the Sofitel New York in New York, New York on September 27, 2016. Ocera’s presentation will take place in the Track 4 Orleans Room at 12:00 PM Eastern Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
OCRX-G
Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109
